OncoMatch/Clinical Trials/NCT07768436
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
Is NCT07768436 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including CMF Regimen and Paclitaxel for adenocarcinoma of the breast.
Treatment: CMF Regimen · Paclitaxel — The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Biomarker criteria
Excluded: HER2 (ERBB2) overexpression
Her 2 Neu positive 3+/amplified breast cancer
Excluded: HER2 (ERBB2) overexpression
Cohort 1 only: Patients have any histology except Her 2 Neu positive in the adjuvant or neoadjuvant setting
Disease stage
Excluded: Stage IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: carboplatin/paclitaxel-based chemotherapy (carboplatin, paclitaxel, pembrolizumab) — neoadjuvant
Cohort 2 only: Patients have received at least 1 dose of carboplatin/paclitaxel +/- pembrolizumab in the neoadjuvant setting
Cannot have received: chemotherapy
Exception: within 1 year of study enrollment
No prior chemotherapy within 1 year of study enrollment
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3; Platelets ≥ 100,000 cells/mm3
Kidney function
Creatinine clearance (CrCL) of >30 mL/min by the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 x institutional ULN (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled); AST and ALT ≤3 x institutional ULN
Adequate hematologic function defined as follows: ANC ≥ 1,500 cells/mm3; Platelets ≥ 100,000 cells/mm3. Adequate renal function defined as follows: CrCL >30 mL/min by the Cockcroft-Gault formula. Adequate hepatic function defined as follows: Total bilirubin ≤ 1.5 x institutional ULN (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled); AST and ALT ≤3 x institutional ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07768436 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy disqualifies patients from enrollment.
Are patients with ERBB2 alterations eligible?
No. ERBB2 overexpression is an exclusion criterion.
Are patients with ERBB2 alterations eligible?
No. ERBB2 overexpression is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify